

# Systematic mapping of functional enhancer-promoter connections with CRISPR interference

Charles P. Fulco,<sup>1,2</sup> Mathias Munschauer,<sup>1</sup> Rockwell Anyoha,<sup>1</sup> Glen Munson,<sup>1</sup> Sharon R. Grossman,<sup>1,3,4</sup> Elizabeth M. Perez,<sup>1</sup> Michael Kane,<sup>1</sup> Brian Cleary,<sup>1,5</sup> Eric S. Lander,<sup>1,2,4\*\*†</sup> Jesse M. Engreitz<sup>1\*†</sup>

<sup>1</sup>Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. <sup>2</sup>Department of Systems Biology, Harvard Medical School, Boston, MA 02114, USA. <sup>3</sup>Division of Health Sciences and Technology, MIT, Cambridge, MA 02139, USA. <sup>4</sup>Department of Biology, MIT, Cambridge, MA 02139, USA. <sup>5</sup>Computational and Systems Biology Program, MIT, Cambridge, MA 02139, USA.

\*These authors contributed equally to this work.

†Corresponding author. Email: engreitz@broadinstitute.org (J.M.E.); lander@broadinstitute.org (E.S.L.)

**Gene expression in mammals is regulated by noncoding elements that can impact physiology and disease, yet the functions and target genes of most noncoding elements remain unknown. We present a high-throughput approach that uses CRISPR interference (CRISPRi) to discover regulatory elements and identify their target genes. We assess >1 megabase (Mb) of sequence in the vicinity of 2 essential transcription factors, *MYC* and *GATA1*, and identify 9 distal enhancers that control gene expression and cellular proliferation. Quantitative features of chromatin state and chromosome conformation distinguish the 7 enhancers that regulate *MYC* from other elements that do not, suggesting a strategy for predicting enhancer-promoter connectivity. This CRISPRi-based approach can be applied to dissect transcriptional networks and interpret the contributions of noncoding genetic variation to human disease.**

A fundamental goal in modern biology is to identify and characterize the noncoding regulatory elements that control gene expression in development and disease, yet we have lacked systematic approaches to do so. Studies of individual regulatory elements have revealed principles of their function, such as the ability of enhancers to recruit activating transcription factors, modify chromatin state, and physically interact with target genes (1, 2). From these insights, systematic mapping of chromatin state and chromosome conformation across cell types has been used to identify putative regulatory elements (3–6). However, these measurements do not determine which (if any) genes are regulated or assess the quantitative effects on gene expression. Indeed, the rules that connect regulatory elements with their target genes in the genome appear to be complex. Regulatory elements do not necessarily affect the closest gene, but instead may act across long distances (7, 8). It remains unclear how many regulatory elements control any given gene, or how many genes are regulated by any given element (2, 3, 8).

We developed a high-throughput approach that utilizes the programmable properties of CRISPR/Cas9 to characterize the regulatory functions of noncoding elements in their native contexts. We use pooled CRISPR screens in combination with CRISPR interference (CRISPRi)—which alters chromatin state at targeted loci through recruitment of a KRAB effector domain fused to catalytically dead Cas9 (dCas9) (9–12)—to simultaneously characterize the regula-

ry effects of up to 1 Mb of sequence on a gene of interest (Fig. 1A) (13).

We studied two gene loci, *GATA1* and *MYC*, that affect proliferation of K562 erythroleukemia cells in a dose-dependent manner (fig. S1). This allowed us to search for regulatory elements that quantitatively tune *GATA1* or *MYC* expression using a proliferation-based pooled assay (Fig. 1A). Importantly, *GATA1* and *MYC* are not located near other strongly essential genes (fig. S1); thus, proliferation defects caused by sgRNAs targeted to sequences near these genes can be attributed to elements regulating *GATA1* or *MYC*. We designed a library containing 98,000 sgRNAs tiling across a total of 1.29 Mb of genomic sequence around *GATA1* and *MYC* as well as 85 kb of control noncoding regions (13). We infected K562 cells expressing KRAB-dCas9 under a doxycycline-inducible promoter with a lentiviral sgRNA library and sequenced the representation of sgRNAs before and after growing cells in doxycycline for 14 population doublings (Fig. 1A). As expected, internal control sgRNAs targeting the promoters of known essential genes (10) were depleted (fig. S2A) and correlated across biological replicates ( $R = 0.91$ , fig. S2B).

We examined the quantitative depletion of sgRNAs in a 74 kb region surrounding *GATA1*, which encodes a key erythroid transcription factor (Fig. 1B). Because the efficiency of different sgRNAs for CRISPRi can vary dramatically (10), we used a sliding window approach, averaging the scores of 20 consecutive sgRNAs and assessing the false dis-

covery rate (FDR) of this metric through comparison to negative control, non-essential regions (13) (fig. S3). Because the average spacing between consecutive sgRNAs was 16 bp, the regions targeted by 20 consecutive sgRNA spanned an average of 314 bp (fig. S3, C and D). With this approach, the window with the highest score (strongest depletion) overlapped the *GATA1* TSS itself (Fig. 1B and fig. S3F). In addition, we identified 3 distal elements that significantly affected cellular proliferation (FDR < 0.05, Fig. 1B) (13). One such element (e-GATA1) is located ~3.6 kb upstream of *GATA1* and corresponds to a DNase I hypersensitive site (DHS) marked by H3K27ac (Fig. 1C); notably, this element shows high sequence conservation among vertebrates, and the syntenic sequence in mouse is required for proper *Gata1* expression in murine erythroid progenitor cells (14). The second distal element (e-HDAC6) corresponds to a conserved DHS located ~1.5 kb upstream of *HDAC6* (Fig. 1C). A third significant element is located at a DHS near the promoter of *GLOD5*, which itself is not essential and only weakly expressed in K562 cells. The first two elements overlap *GATA1* ChIP-Seq peaks and sequence motifs (Fig. 1C), consistent with known auto-regulatory loops in which *GATA1* activates its own expression (15). All three elements reside in close linear and spatial proximity to *GATA1* (fig. S4A). Finally, multiple regions in the gene body of *GATA1* scored as significantly depleted in the screen (Fig. 1B), but, because recruitment of KRAB-dCas9 to these sites may directly interfere with transcription (9), we focused on distal regulatory elements in subsequent analysis.

To characterize these elements, we measured *GATA1* expression using quantitative PCR in cell lines stably expressing individual sgRNAs (13). As expected, targeting KRAB-dCas9 to the *GATA1* TSS reduced *GATA1* expression (76% reduction, Fig. 1D). sgRNAs targeting e-GATA1 or e-HDAC6 reduced *GATA1* expression by 44% and 33%, respectively (Fig. 1D), and affected the expression of genes known to be regulated by the *GATA1* transcription factor (fig. S4B), confirming that these enhancers regulate *GATA1*. In contrast, sgRNAs targeting the *HDAC6* TSS did not reduce *GATA1* expression despite reducing *HDAC6* expression (Fig. 1D), indicating that (i) the pooled screen accurately predicted that this region does not reduce *GATA1* expression and (ii) the effects seen for the e-GATA1 and e-HDAC6 sgRNAs are not due to general effects of targeting KRAB-dCas9 to the gene neighborhood. Additionally, both e-GATA1 and e-HDAC6 can activate the expression of a plasmid-based reporter gene (fig. S4C) (13). Together, these results support the specificity of this CRISPRi-based approach and demonstrate that e-GATA1 and e-HDAC6 quantitatively control *GATA1* expression in K562 cells.

Considering the close proximity of *GATA1* to *HDAC6* (Fig. 1B and fig. S4A), we tested whether this pair of en-

hancers also regulates *HDAC6*. sgRNAs targeting e-GATA1 and e-HDAC6 reduced *HDAC6* expression by 42% and 22%, respectively, comparable to their effects on *GATA1* (Fig. 1D). Intriguingly, inhibition of the *GATA1* promoter led to an increase in *HDAC6* expression (+47%, Fig. 1D), and inhibition of the *HDAC6* promoter modestly activated *GATA1* (+9%, Fig. 1D); this suggests that *GATA1* and *HDAC6* may compete for these shared enhancers, similar to observations for other pairs of neighboring genes (16, 17). Interestingly, histone deacetylases are required for erythropoiesis (18) and *HDAC6* has been implicated in cellular proliferation in multiple cancers (19). Thus, although *HDAC6* does not score as essential in proliferation assays in K562 cells, it is possible that proliferative defects observed upon inhibition of e-GATA1 or e-HDAC6 result from the combined effects on both *GATA1* and *HDAC6* expression (13), and the genomic proximity of these genes may be important for coordinating their expression in vivo. These observations indicate a complex connectivity between enhancers and promoters in their native genomic contexts (fig. S4D).

We next investigated the *cis* regulatory architecture of *MYC*, a critical transcription factor encoded within a 3-Mb topological domain that contains hundreds of putative enhancers. Several enhancers in this domain regulate *MYC* in other cell types (13), but chromatin state varies dramatically across cell types and it is unclear which of these elements regulate *MYC* in a given cell type. Notably, the domain contains over 60 genetic haplotypes associated (through genome-wide association studies) with human phenotypes, including cancer susceptibility (20).

To identify elements that regulate *MYC* in K562 cells, we tiled sgRNAs across ~1.2 Mb of sequence in this topological domain (Fig. 2A). A sliding window analysis identified several regions whose inhibition reproducibly reduced cellular proliferation, including a known promoter-proximal element located 2 kb upstream of the *MYC* TSS (fig. S5A) (21), the transcribed region of the *MYC* gene body (fig. S5A), and seven distal regions (labeled e1 through e7) located between 0.16 and 1.9 Mb downstream of *MYC* (Fig. 2A and fig. S5, B and C). We also identified two regions that significantly *increased* cell proliferation (r1 and r2), and thus may repress *MYC* expression (Fig. 2A and fig. S5, D and E) (13).

Each of the seven putative activating elements is marked by high levels of DNase I hypersensitivity (Fig. 2A); is bound by multiple transcription factors (fig. S6A); and shows patches of sequence conservation across mammals (Fig. 2B). Each enhancer frequently contacts the *MYC* promoter in three dimensions as assayed by Hi-C and ChIA-PET in K562 cells (Fig. 2A) (3, 6); elements e5 and e6/7 form very long-range (>1.8 Mb) loops to the *MYC* promoter and are located within 10 kb of CTCF ChIP-Seq peaks with motifs oriented toward *MYC* (fig. S5, B and C), consistent with the conver-

gent rule for CTCF-mediated chromatin loops (6). Two elements (e3 and e4) correspond to alternative TSSs for the long noncoding RNA PVT1 (Fig. 2A); knockdown experiments indicate that the mature PVT1 RNA transcript itself is likely not essential in K562 cells (fig. S1) and so e3 and e4 likely affect cellular proliferation through direct regulation of *MYC* (13).

We experimentally characterized these seven activating elements to test whether they regulate *MYC*. CRISPRi inhibition of each of these elements with individual sgRNAs led to proliferation defects in a competitive growth assay (fig. S6B) and led to a 9-62% reduction in *MYC* expression (Fig. 2C). The magnitude of the change in gene expression correlated with the proliferation defect, consistent with a quantitative relationship between cell growth and precise *MYC* expression levels (Pearson  $R = 0.92$ , Fig. 2D). In a plasmid-based reporter assay, each putative regulatory element led to >5-fold up-regulation of a reporter gene relative to a control sequence (fig. S6C) (13). For a subset of the elements (e2, e3, and e4), we generated clonal cell lines containing genetic deletions on one or two of the three chromosome 8 alleles (K562 cells are triploid) and measured the expression of *MYC* from each allele (13). For each element, we found that genetic deletions reduced *MYC* expression from the corresponding allele(s), confirming our CRISPRi results (fig. S7). Together, these data support the hypothesis that these seven elements, spanning 1.6 Mb of noncoding sequence, act as enhancers to control *MYC* expression and cellular proliferation.

In addition to e1-e7, we characterized one noncoding element (NS1) that did *not* score in the screen (Fig. 2A). In K562 cells, NS1 displays strong DHS and H3K27ac occupancy, binds to multiple transcription factors (fig. S6A), and participates in a long-range chromatin loop to the *MYC* promoter (Fig. 2A). In a lung adenocarcinoma cell line, NS1 regulates *MYC* as assayed by CRISPRi inhibition with individual sgRNAs (22). Accordingly, we wondered whether NS1 regulates *MYC* in K562 cells despite not being detected as such in our CRISPRi screen. To explore this possibility, we targeted KRAB-dCas9 to NS1 with individual sgRNAs in K562 cells and found that CRISPRi successfully reduced H3K27ac occupancy to an extent similar to that observed when targeting other *MYC* enhancers (fig. S6D). Despite affecting chromatin state at NS1 in K562 cells, these sgRNAs did not substantially impact cellular proliferation or *MYC* expression (Fig. 2, C and D), consistent with the results from the pooled screen. These observations support the ability of the CRISPRi screening approach to distinguish elements that do and do not regulate a given gene. However, we note that some regulatory elements, such as those that act redundantly with others in the locus, may not be discoverable by this method (13).

The ability to systematically test gene regulatory elements will help to train predictive models of functional enhancer-promoter connectivity. Notably, existing annotations and catalogs of enhancer-promoter predictions performed poorly at distinguishing e1-e7 from enhancers that do not impact *MYC* expression (13). For example, ENCODE annotates 185 Kb of sequence in this domain as putative “strong enhancer” in K562 cells (Fig. 2A), but only 8% of this sequence, corresponding to e1-e7, appears to regulate *MYC*. We sought to improve the ability to predict enhancers and connect them with genes that they regulate. When we examined chromatin state maps (including DHS, H3K27ac and Hi-C), we found that quantitative DHS or H3K27ac signal could distinguish most of the seven *MYC* enhancers but ranked them in the wrong order (fig. S8A): for example, e5 shows the strongest DHS signal yet has the weakest effect on *MYC* expression (Fig. 2). Accordingly, we considered a framework (fig. S8B) wherein the impact of an enhancer on gene expression is determined both by its intrinsic activity level (for which we use quantitative DHS and H3K27ac levels as a proxy) and the frequency at which the enhancer contacts its target promoter (for which we use Hi-C data as a proxy) (13). This metric correctly ranked 6 of the 7 distal enhancers as the most important of 93 DHS elements in K562 cells (Fig. 2E) and provided a reasonable ordering of their relative effects (Spearman correlation = 0.79). We note that this approach did not perfectly distinguish between enhancers that do and do not regulate *MYC*: NS1 was ranked 7 and e6 was ranked 11. Nonetheless, quantitative measures of chromatin state and chromosome conformation are strongly predictive of enhancers that regulate *MYC* in K562 cells.

To determine whether this approach might be applicable in other cellular contexts, we examined 4 *MYC* enhancers identified in other cell types (Fig. 3, A and B) (13). In each case our metric ranked these known elements among the 3 most important in the corresponding cell type (Fig. 3B). We also identified multiple instances where elements predicted to regulate *MYC* in one or more cell types harbor single nucleotide polymorphisms (SNPs) associated with human traits including cancer susceptibility and height (Fig. 3, C and D, and table S1). Additional CRISPRi-based functional mapping in other cell types and gene loci might allow the derivation of general models to predict functional enhancer-promoter connections and help to understand noncoding genetic variation.

In summary, CRISPRi screens can accurately identify and characterize the regulatory functions and connectivity of noncoding elements. In the *MYC* and *GATA1* loci, CRISPRi reveals complex and non-obvious dependencies between multiple genes and enhancers, including relationships that suggest regulation of multiple genes by the same enhancer,



coordinated activity of multiple enhancers to control a single gene, and competition between neighboring promoters. Thus, learning the principles and connectivity of transcriptional networks requires dissecting putative regulatory elements in their native genomic contexts.

While we used cellular proliferation as a readout to investigate 2 essential genes, this CRISPRi approach can be applied to identify regulatory elements that control an arbitrary gene or phenotype of interest through alternative assays, for example by tagging an endogenous gene locus with green fluorescent protein (GFP) and sorting cells by GFP expression (23).

Together with complementary methods using catalytically active Cas9 (13, 23–25), CRISPRi-based functional mapping provides a broadly applicable approach (13) to dissect transcriptional networks and interpret the contributions of noncoding genetic variation in gene regulatory elements to human disease.

## REFERENCES AND NOTES

1. M. Bulger, M. Groudine, Functional and mechanistic diversity of distal transcription enhancers. *Cell* **144**, 327–339 (2011). doi:10.1016/j.cell.2011.01.024 Medline
2. F. Spitz, E. E. M. Furlong, Transcription factors: From enhancer binding to developmental control. *Nat. Rev. Genet.* **13**, 613–626 (2012). doi:10.1038/nrg3207 Medline
3. G. Li, X. Ruan, R. K. Auerbach, K. S. Sandhu, M. Zheng, P. Wang, H. M. Poh, Y. Goh, J. Lim, J. Zhang, H. S. Sim, S. Q. Peh, F. H. Mulawadi, C. T. Ong, Y. L. Orlov, S. Hong, Z. Zhang, S. Landt, D. Raha, G. Euskirchen, C.-L. Wei, W. Ge, H. Wang, C. Davis, K. I. Fisher-Aylor, A. Mortazavi, M. Gerstein, T. Gingeras, B. Wold, Y. Sun, M. J. Fullwood, E. Cheung, E. Liu, W.-K. Sung, M. Snyder, Y. Ruan, Extensive promoter-centered chromatin interactions provide a topological basis for transcription regulation. *Cell* **148**, 84–98 (2012). doi:10.1016/j.cell.2011.12.014 Medline
4. I. Dunham, A. Kundaje, S. F. Aldred, P. J. Collins, C. A. Davis, F. Doyle, C. B. Epstein, S. Fietze, J. Harrow, R. Kaul, J. Khatun, B. R. Lajoie, S. G. Landt, B.-K. Lee, F. Pauli, K. R. Rosenbloom, P. Sabo, A. Safi, A. Sanyal, N. Shores, J. M. Simon, L. Song, N. D. Trinklein, R. C. Altshuler, E. Birney, J. B. Brown, C. Cheng, S. Djebali, X. Dong, I. Dunham, J. Ernst, T. S. Furey, M. Gerstein, B. Giardine, M. Greven, R. C. Hardison, R. S. Harris, J. Herrero, M. M. Hoffman, S. Iyer, M. Kellis, J. Khatun, P. Kheradpour, A. Kundaje, T. Lassmann, Q. Li, X. Lin, G. K. Marinov, A. Merkel, A. Mortazavi, S. C. J. Parker, T. E. Reddy, J. Rozowsky, F. Schlesinger, R. E. Thurman, J. Wang, L. D. Ward, T. W. Whitfield, S. P. Wilder, W. Wu, H. S. Xi, K. Y. Yip, J. Zhuang, B. E. Bernstein, E. Birney, I. Dunham, E. D. Green, C. Gunter, M. Snyder, M. J. Pazin, R. F. Lowdon, L. A. L. Dillon, L. B. Adams, C. J. Kelly, J. Zhang, J. R. Wexler, E. D. Green, P. J. Good, E. A. Feingold, B. E. Bernstein, E. Birney, G. E. Crawford, J. Dekker, L. Elnitski, P. J. Farnham, M. Gerstein, M. C. Giddings, T. R. Gingeras, E. D. Green, R. Guigó, R. C. Hardison, T. J. Hubbard, M. Kellis, W. J. Kent, J. D. Lieb, E. H. Margulies, R. M. Myers, M. Snyder, J. A. Stamatoyannopoulos, S. A. Tenenbaum, Z. Weng, K. P. White, B. Wold, J. Khatun, Y. Yu, J. Wrobel, B. A. Risk, H. P. Gunawardena, H. C. Kuiper, C. W. Maier, L. Xie, X. Chen, M. C. Giddings, B. E. Bernstein, C. B. Epstein, N. Shores, J. Ernst, P. Kheradpour, T. S. Mikkelsen, S. Gillespie, A. Goren, O. Ram, X. Zhang, L. Wang, R. Issner, M. J. Coyne, T. Durham, M. Ku, T. Truong, L. D. Ward, R. C. Altshuler, M. L. Eaton, M. Kellis, S. Djebali, C. A. Davis, A. Merkel, A. Dobin, T. Lassmann, A. Mortazavi, A. Tanzer, J. Lagarde, W. Lin, F. Schlesinger, C. Xue, G. K. Marinov, J. Khatun, B. A. Williams, C. Zaleski, J. Rozowsky, M. Röder, F. Kokocinski, R. F. Abdelhamid, T. Alioto, I. Antoshechkin, M. T. Baer, P. Batut, I. Bell, K. Bell, S. Chakraborty, X. Chen, J. Chrast, J. Curado, T. Derrien, J. Drenkow, E. Dumais, J. Dumais, R. Dutttagupta, M. Fastuca, K. Fejes-Toth, P. Ferreira, S. Foissac, M. J. Fullwood, H. Gao, D. Gonzalez, A. Gordon, H. P. Gunawardena, C. Howald, S. Jha, R. Johnson, P. Kapranov, B. King, C. Kingswood, G. Li, O. J. Luo, E. Park, J. B. Preall, K. Presaud, P. Ribeca, B. A. Risk, D. Robyr, X. Ruan, M. Sammeth, K. S. Sandhu, L. Schaeffer, L.-H. See, A. Shahab, J. Skancke, A. M. Suzuki, H. Takahashi, H. Tilgner, D. Trout, N. Walters, H. Wang, J. Wrobel, Y. Yu, Y. Hayashizaki, J. Harrow, M. Gerstein, T. J. Hubbard, A. Reymond, S. E. Antonarakis, G. J. Hannon, M. C. Giddings, Y. Ruan, B. Wold, P. Carninci, R. Guigó, T. R. Gingeras, K. R. Rosenbloom, C. A. Sloan, K. Learned, V. S. Malladi, M. C. Wong, G. P. Barber, M. S. Cline, T. R. Dreszer, S. G. Heitner, D. Karolchik, W. J. Kent, V. M. Kirkup, L. R. Meyer, J. C. Long, M. Maddren, B. J. Raney, T. S. Furey, L. Song, L. L. Grasfeder, P. G. Giresi, B.-K. Lee, A. Battenhouse, N. C. Sheffield, J. M. Simon, K. A. Showers, A. Safi, D. London, A. A. Bhinghe, C. Shestak, M. R. Schaner, S. Ki Kim, Z. Z. Zhang, P. A. Mieczkowski, J. O. Mieczkowska, Z. Liu, R. M. McDaniell, Y. Ni, N. U. Rashid, M. J. Kim, S. Adar, Z. Zhang, T. Wang, D. Winter, D. Keefe, E. Birney, V. R. Iyer, J. D. Lieb, G. E. Crawford, G. Li, K. S. Sandhu, M. Zheng, P. Wang, O. J. Luo, A. Shahab, M. J. Fullwood, X. Ruan, Y. Ruan, R. M. Myers, F. Pauli, B. A. Williams, J. Gertz, G. K. Marinov, T. E. Reddy, J. Vielmetter, E. Partridge, D. Trout, K. E. Varley, C. Gasper, A. Bansal, S. Pepke, P. Jain, H. Amrhein, K. M. Bowling, M. Anaya, M. K. Cross, B. King, M. A. Muratet, I. Antoshechkin, K. M. Newberry, K. McCue, A. S. Nesmith, K. I. Fisher-Aylor, B. Pusey, G. DeSalvo, S. L. Parker, S. Balasubramanian, N. S. Davis, S. K. Meadows, T. Eggleston, C. Gunter, J. S. Newberry, S. E. Levy, D. M. Absher, A. Mortazavi, W. H. Wong, B. Wold, M. J. Blow, A. Visel, L. A. Pennachio, L. Elnitski, E. H. Margulies, S. C. J. Parker, H. M. Petrykowska, A. Abyzov, B. Aken, D. Barrell, G. Barson, A. Berry, A. Bignell, V. Boychenko, G. Bussotti, J. Chrast, C. Davidson, T. Derrien, G. Despacio-Reyes, M. Diekhans, I. Ezkurdia, A. Frankish, J. Gilbert, J. M. Gonzalez, E. Griffiths, R. Harte, D. A. Hendrix, C. Howald, T. Hunt, I. Jungreis, M. Kay, E. Khurana, F. Kokocinski, J. Leng, M. F. Lin, J. Loveland, Z. Lu, D. Manthavadi, M. Mariotti, J. Mudge, G. Mukherjee, C. Notredame, B. Pei, J. M. Rodriguez, G. Saunders, A. Sboner, S. Searle, C. Sisu, C. Snow, C. Steward, A. Tanzer, E. Tapanari, M. L. Tress, M. J. van Baren, N. Walters, S. Washietl, L. Wilming, A. Zadissa, Z. Zhang, M. Brent, D. Haussler, M. Kellis, A. Valencia, M. Gerstein, A. Reymond, R. Guigó, J. Harrow, T. J. Hubbard, S. G. Landt, S. Fietze, A. Abyzov, N. Addleman, R. P. Alexander, R. K. Auerbach, S. Balasubramanian, K. Bettinger, N. Bhardwaj, A. P. Boyle, A. R. Cao, P. Cayting, A. Charos, Y. Cheng, C. Cheng, C. Eastman, G. Euskirchen, J. D. Fleming, F. Grubert, L. Habegger, M. Hariharan, A. Harmanci, S. Iyengar, V. X. Jin, K. J. Karczewski, M. Kasowski, P. Lacroute, H. Lam, N. Lamarre-Vincent, J. Leng, J. Lian, M. Lindahl-Allen, R. Min, B. Miotto, H. Monahan, Z. Moqtaderi, X. J. Mu, H. O'Geen, Z. Ouyang, D. Patacsil, B. Pei, D. Raha, L. Ramirez, B. Reed, J. Rozowsky, A. Sboner, M. Shi, C. Sisu, T. Slifer, H. Witt, L. Wu, X. Xu, K.-K. Yan, X. Yang, K. Y. Yip, Z. Zhang, K. Struhl, S. M. Weissman, M. Gerstein, P. J. Farnham, M. Snyder, S. A. Tenenbaum, L. O. Penalva, F. Doyle, S. Karmakar, S. G. Landt, R. R. Bhanvadia, A. Choudhury, M. Domanus, L. Ma, J. Moran, D. Patacsil, T. Slifer, A. Victorians, X. Yang, M. Snyder, K. P. White, T. Auer, L. Centanin, M. Eichenlaub, F. Gruhl, S. Heermann, B. Hoekendorf, D. Inoue, T. Kellner, S. Kirchmaier, C. Mueller, R. Reinhardt, L. Schertel, S. Schneider, R. Sinn, B. Wittbrodt, J. Wittbrodt, Z. Weng, T. W. Whitfield, J. Wang, P. J. Collins, S. F. Aldred, N. D. Trinklein, E. C. Partridge, R. M. Myers, J. Dekker, G. Jain, B. R. Lajoie, A. Sanyal, G. Balasundaram, D. L. Bates, R. Byron, T. K. Canfield, M. J. Diegel, D. Dunn, A. K. Ebersol, T. Frum, K. Garg, E. Gist, R. S. Hansen, L. Boatman, E. Haugen, R. Humbert, G. Jain, A. K. Johnson, E. M. Johnson, T. V. Kutayavin, B. R. Lajoie, K. Lee, D. Lotakis, M. T. Maurano, S. J. Neph, F. V. Neri, E. D. Nguyen, H. Qu, A. P. Reynolds, V. Roach, E. Rynes, P. Sabo, M. E. Sanchez, R. S. Sandstrom, A. Sanyal, A. O. Shafer, A. B. Stergachis, S. Thomas, R. E. Thurman, B. Vernot, J. Vierstra, S. Vong, H. Wang, M. A. Weaver, Y. Yan, M. Zhang, J. M. Akey, M. Bender, M. O. Dorschner, M. Groudine, M. J. MacCoss, P. Navas, G. Stamatoyannopoulos, R. Kaul, J. Dekker, J. A. Stamatoyannopoulos, I. Dunham, K. Beal, A. Brazma, P. Flicek, J. Herrero, N. Johnson, D. Keefe, M. Lukk, N. M. Luscombe, D. Sobral, J. M. Vaquerizas, S. P. Wilder, S. Batzoglou, A. Sidow, N. Hussami, S. Kyriazopoulou-Panagiotopoulou, M. W. Libbrecht, M. A. Schaub, A. Kundaje, R. C. Hardison, W. Miller, B. Giardine, R. S. Harris, W. Wu, P. J. Bickel, B. Banfai, N. P. Boley, J. B. Brown, H. Huang, Q. Li, J. J. Li, W. S. Noble, J. A. Billes, O. J. Buske, M. M. Hoffman, A. D. Sahu, P. V. Kharchenko, P. J. Park, D. Baker, J. Taylor, Z. Weng, S. Iyer, X. Dong, M. Greven, X. Lin, J. Wang, H. S. Xi, J. Zhuang, M. Gerstein, R. P. Alexander, S. Balasubramanian, C. Cheng, A. Harmanci, L. Lohovsky, R. Min, X. J. Mu, J. Rozowsky, K.-K. Yan, K. Y. Yip, E. Birney; ENCODE Project Consortium, An

- integrated encyclopedia of DNA elements in the human genome. *Nature* **489**, 57–74 (2012). [doi:10.1038/nature11247](https://doi.org/10.1038/nature11247) [Medline](#)
5. A. Kundaje, W. Meuleman, J. Ernst, M. Bilenky, A. Yen, A. Heravi-Moussavi, P. Kheradpour, Z. Zhang, J. Wang, M. J. Ziller, V. Amin, J. W. Whitaker, M. D. Schultz, L. D. Ward, A. Sarkar, G. Quon, R. S. Sandstrom, M. L. Eaton, Y.-C. Wu, A. R. Pfennig, X. Wang, M. Claussnitzer, Y. Liu, C. Coarfa, R. A. Harris, N. Shores, C. B. Epstein, E. Gjonneska, D. Leung, W. Xie, R. D. Hawkins, R. Lister, C. Hong, P. Gascard, A. J. Mungall, R. Moore, E. Chuah, A. Tam, T. K. Canfield, R. S. Hansen, R. Kaul, P. J. Sabo, M. S. Bansal, A. Carles, J. R. Dixon, K. H. Farh, S. Feizi, R. Karlic, A. R. Kim, A. Kulkarni, D. Li, R. Lowdon, G. Elliott, T. R. Mercer, S. J. Neph, V. Onuchic, P. Polak, N. Rajagopal, P. Ray, R. C. Sallari, K. T. Siebenthal, N. A. Sinnott-Armstrong, M. Stevens, R. E. Thurman, J. Wu, B. Zhang, X. Zhou, A. E. Beaudet, L. A. Boyer, P. L. De Jager, P. J. Farnham, S. J. Fisher, D. Haussler, S. J. Jones, W. Li, M. A. Marra, M. T. McManus, S. Sunyaev, J. A. Thomson, T. D. Tlsty, L. H. Tsai, W. Wang, R. A. Waterland, M. Q. Zhang, L. H. Chadwick, B. E. Bernstein, J. F. Costello, J. R. Ecker, M. Hirst, A. Meissner, A. Milosavljevic, B. Ren, J. A. Stamatoyannopoulos, T. Wang, M. Kellis, T. Durham, L. Echipare, L. Edsall, D. Flowers, O. Genbacev-Krtolica, C. Gifford, S. Gillespie, E. Giste, I. A. Glass, A. Gnirke, M. Gormley, H. Gu, J. Gu, D. A. Hafler, M. J. Hangauer, M. Hariharan, M. Hatan, E. Haugen, Y. He, S. Heimfeld, S. Herlofsen, Z. Hou, R. Humbert, R. Issner, A. R. Jackson, H. Jia, P. Jiang, A. K. Johnson, T. Kadlecak, B. Kamoh, M. Kapidzic, J. Kent, A. Kim, M. Kleinewietfeld, S. Klugman, J. Krishnan, S. Kuan, T. Kutayavin, A.-Y. Lee, K. Lee, J. Li, N. Li, Y. Li, K. L. Ligon, S. Lin, Y. Lin, J. Liu, Y. Liu, C. J. Luckey, Y. P. Ma, C. Maire, A. Marson, J. S. Mattick, M. Mayo, M. McMaster, H. Metsky, T. Mikkelsen, D. Miller, M. Miri, E. Mukame, R. P. Nagarajan, F. Neri, J. Nery, T. Nguyen, H. O'Geen, S. Paithankar, T. Papayannopoulou, M. Pelizzola, P. Plettner, N. E. Propson, S. Raghuraman, B. J. Raney, A. Raubitschek, A. P. Reynolds, H. Richards, K. Riehle, P. Rinaudo, J. F. Robinson, N. B. Rockweiler, E. Rosen, E. Rynes, J. Schein, R. Sears, T. Sejnowski, A. Shafer, L. Shen, R. Shoemaker, M. Sigaroudinia, I. Slukvin, S. Stehling-Sun, R. Stewart, S. L. Subramanian, K. Suknutha, S. Swanson, S. Tian, H. Tilden, L. Tsai, M. Urich, I. Vaughn, J. Vierstra, S. Vong, U. Wagner, H. Wang, T. Wang, Y. Wang, A. Weiss, H. Whitton, A. Wildberg, H. Witt, K.-J. Won, M. Xie, X. Xing, I. Xu, Z. Xuan, Z. Ye, C. Yen, P. Yu, X. Zhang, X. Zhang, J. Zhao, Y. Zhou, J. Zhu, Y. Zhu, S. Ziegler, A. E. Beaudet, L. A. Boyer, P. L. De Jager, P. J. Farnham, S. J. Fisher, D. Haussler, S. J. M. Jones, W. Li, M. A. Marra, M. T. McManus, S. Sunyaev, J. A. Thomson, T. D. Tlsty, L.-H. Tsai, W. Wang, R. A. Waterland, M. Q. Zhang, L. H. Chadwick, B. E. Bernstein, J. F. Costello, J. R. Ecker, M. Hirst, A. Meissner, A. Milosavljevic, B. Ren, J. A. Stamatoyannopoulos, T. Wang, M. Kellis, A. Kundaje, W. Meuleman, J. Ernst, M. Bilenky, A. Yen, A. Heravi-Moussavi, P. Kheradpour, Z. Zhang, J. Wang, M. J. Ziller, V. Amin, J. W. Whitaker, M. D. Schultz, L. D. Ward, A. Sarkar, G. Quon, R. S. Sandstrom, M. L. Eaton, Y.-C. Wu, A. R. Pfennig, X. Wang, M. Claussnitzer, Y. Liu, C. Coarfa, R. A. Harris, N. Shores, C. B. Epstein, E. Gjonneska, D. Leung, W. Xie, R. D. Hawkins, R. Lister, C. Hong, P. Gascard, A. J. Mungall, R. Moore, E. Chuah, A. Tam, T. K. Canfield, R. S. Hansen, R. Kaul, P. J. Sabo, M. S. Bansal, A. Carles, J. R. Dixon, K.-H. Farh, S. Feizi, R. Karlic, A.-R. Kim, A. Kulkarni, D. Li, R. Lowdon, G. N. Elliott, T. R. Mercer, S. J. Neph, V. Onuchic, P. Polak, N. Rajagopal, P. Ray, R. C. Sallari, K. T. Siebenthal, N. A. Sinnott-Armstrong, M. Stevens, R. E. Thurman, J. Wu, B. Zhang, X. Zhou, A. E. Beaudet, L. A. Boyer, P. L. De Jager, P. J. Farnham, S. J. Fisher, D. Haussler, S. J. M. Jones, W. Li, M. A. Marra, M. T. McManus, S. Sunyaev, J. A. Thomson, T. D. Tlsty, L.-H. Tsai, W. Wang, R. A. Waterland, M. Q. Zhang, L. H. Chadwick, B. E. Bernstein, J. F. Costello, J. R. Ecker, M. Hirst, A. Meissner, A. Milosavljevic, B. Ren, J. A. Stamatoyannopoulos, T. Wang, M. Kellis; Roadmap Epigenomics Consortium, Integrative analysis of 111 reference human epigenomes. *Nature* **518**, 317–330 (2015). [doi:10.1038/nature14248](https://doi.org/10.1038/nature14248) [Medline](#)
  6. S. S. P. Rao, M. H. Huntley, N. C. Durand, E. K. Stamenova, I. D. Bochkov, J. T. Robinson, A. L. Sanborn, I. Machol, A. D. Omer, E. S. Lander, E. L. Aiden, A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping. *Cell* **159**, 1665–1680 (2014). [doi:10.1016/j.cell.2014.11.021](https://doi.org/10.1016/j.cell.2014.11.021) [Medline](#)
  7. D. Shlyueva, G. Stampfel, A. Stark, Transcriptional enhancers: From properties to genome-wide predictions. *Nat. Rev. Genet.* **15**, 272–286 (2014). [doi:10.1038/nrg3682](https://doi.org/10.1038/nrg3682) [Medline](#)
  8. J. van Arensbergen, B. van Steensel, H. J. Bussemaker, In search of the determinants of enhancer-promoter interaction specificity. *Trends Cell Biol.* **24**, 695–702 (2014). [Medline](#)
  9. L. A. Gilbert, M. H. Larson, L. Morsut, Z. Liu, G. A. Brar, S. E. Torres, N. Stern-Ginossar, O. Brandman, E. H. Whitehead, J. A. Doudna, W. A. Lim, J. S. Weissman, L. S. Qi, CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. *Cell* **154**, 442–451 (2013). [doi:10.1016/j.cell.2013.06.044](https://doi.org/10.1016/j.cell.2013.06.044) [Medline](#)
  10. L. A. Gilbert, M. A. Horlbeck, B. Adamson, J. E. Villalta, Y. Chen, E. H. Whitehead, C. Guimaraes, B. Panning, H. L. Ploegh, M. C. Bassik, L. S. Qi, M. Kampmann, J. S. Weissman, Genome-scale CRISPR-mediated control of gene repression and activation. *Cell* **159**, 647–661 (2014). [doi:10.1016/j.cell.2014.09.029](https://doi.org/10.1016/j.cell.2014.09.029) [Medline](#)
  11. N. A. Kearns, R. M. J. Genga, M. S. Enuameh, M. Garber, S. A. Wolfe, R. Maehr, Cas9 effector-mediated regulation of transcription and differentiation in human pluripotent stem cells. *Development* **141**, 219–223 (2014). [doi:10.1242/dev.103341](https://doi.org/10.1242/dev.103341) [Medline](#)
  12. P. I. Thakore, A. M. D'Ipollito, L. Song, A. Safi, N. K. Shivakumar, A. M. Kabadi, T. E. Reddy, G. E. Crawford, C. A. Gersbach, Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. *Nat. Methods* **12**, 1143–1149 (2015). [doi:10.1038/nmeth.3630](https://doi.org/10.1038/nmeth.3630) [Medline](#)
  13. See supplementary materials on Science Online.
  14. M. Suzuki, T. Moriguchi, K. Ohneda, M. Yamamoto, Differential contribution of the *Gata1* gene hematopoietic enhancer to erythroid differentiation. *Mol. Cell. Biol.* **29**, 1163–1175 (2009). [doi:10.1128/MCB.01572-08](https://doi.org/10.1128/MCB.01572-08) [Medline](#)
  15. S. Nishimura, S. Takahashi, T. Kuroha, N. Suwabe, T. Nagasawa, C. Trainor, M. Yamamoto, A GATA box in the GATA-1 gene hematopoietic enhancer is a critical element in the network of GATA factors and sites that regulate this gene. *Mol. Cell. Biol.* **20**, 713–723 (2000). [doi:10.1128/MCB.20.2.713-723.2000](https://doi.org/10.1128/MCB.20.2.713-723.2000) [Medline](#)
  16. O. R. Choi, J. D. Engel, Developmental regulation of beta-globin gene switching. *Cell* **55**, 17–26 (1988). [doi:10.1016/0092-8674\(88\)90005-0](https://doi.org/10.1016/0092-8674(88)90005-0) [Medline](#)
  17. S. Ohtsuki, M. Levine, H. N. Cai, Different core promoters possess distinct regulatory activities in the *Drosophila* embryo. *Genes Dev.* **12**, 547–556 (1998). [doi:10.1101/gad.12.4.547](https://doi.org/10.1101/gad.12.4.547) [Medline](#)
  18. A. Fujieda, N. Katayama, K. Ohishi, K. Yamamura, T. Shibasaki, Y. Sugimoto, E. Miyata, K. Nishi, M. Masuya, H. Ueda, H. Nakajima, H. Shiku, A putative role for histone deacetylase in the differentiation of human erythroid cells. *Int. J. Oncol.* **27**, 743–748 (2005). [Medline](#)
  19. K. J. Falkenberg, R. W. Johnstone, Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. *Nat. Rev. Drug Discov.* **14**, 219 (2015). [doi:10.1038/nrd4579](https://doi.org/10.1038/nrd4579)
  20. T. Burdett *et al.*, The NHGRI-EBI Catalog of published genome-wide association studies. (available at <http://www.ebi.ac.uk/gwas>).
  21. W. M. Gombert, A. Krumm, Targeted deletion of multiple CTCF-binding elements in the human C-MYC gene reveals a requirement for CTCF in C-MYC expression. *PLOS ONE* **4**, e6109 (2009). [doi:10.1371/journal.pone.0006109](https://doi.org/10.1371/journal.pone.0006109) [Medline](#)
  22. X. Zhang, P. S. Choi, J. M. Francis, M. Imielinski, H. Watanabe, A. D. Cherniack, M. Meyerson, Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers. *Nat. Genet.* **48**, 176–182 (2016). [doi:10.1038/ng.3470](https://doi.org/10.1038/ng.3470) [Medline](#)
  23. N. Rajagopal, S. Srinivasan, K. Kooshesh, Y. Guo, M. D. Edwards, B. Banerjee, T. Syed, B. J. M. Emons, D. K. Gifford, R. I. Sherwood, High-throughput mapping of regulatory DNA. *Nat. Biotechnol.* **34**, 167–174 (2016). [doi:10.1038/nbt.3468](https://doi.org/10.1038/nbt.3468) [Medline](#)
  24. M. C. Canver, E. C. Smith, F. Sher, L. Pinello, N. E. Sanjana, O. Shalem, D. D. Chen, P. G. Schupp, D. S. Vinjamur, S. P. Garcia, S. Luc, R. Kurita, Y. Nakamura, Y. Fujiwara, T. Maeda, G.-C. Yuan, F. Zhang, S. H. Orkin, D. E. Bauer, BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. *Nature* **527**, 192–197 (2015). [doi:10.1038/nature15521](https://doi.org/10.1038/nature15521) [Medline](#)
  25. G. Korkmaz, R. Lopes, A. P. Ugalde, E. Nevedomskaya, R. Han, K. Myacheva, W. Zwart, R. Elkon, R. Agami, Functional genetic screens for enhancer elements in the human genome using CRISPR-Cas9. *Nat. Biotechnol.* **34**, 192–198 (2016). [doi:10.1038/nbt.3450](https://doi.org/10.1038/nbt.3450) [Medline](#)
  26. T. Wang, K. Birsoy, N. W. Hughes, K. M. Krupczak, Y. Post, J. J. Wei, E. S. Lander, D. M. Sabatini, Identification and characterization of essential genes in the human genome. *Science* **350**, 1096–1101 (2015). [doi:10.1126/science.aac7041](https://doi.org/10.1126/science.aac7041) [Medline](#)
  27. D. Levens, You don't muck with MYC. *Genes Cancer* **1**, 547–554

- (2010).[doi:10.1177/1947601910377492](https://doi.org/10.1177/1947601910377492) [Medline](#)
28. P. D. Hsu, D. A. Scott, J. A. Weinstein, F. A. Ran, S. Konermann, V. Agarwala, Y. Li, E. J. Fine, X. Wu, O. Shalem, T. J. Cradick, L. A. Marraffini, G. Bao, F. Zhang, DNA targeting specificity of RNA-guided Cas9 nucleases. *Nat. Biotechnol.* **31**, 827–832 (2013).[doi:10.1038/nbt.2647](https://doi.org/10.1038/nbt.2647) [Medline](#)
  29. M. A. Horlbeck, L. B. Witkowsky, B. Guglielmi, J. M. Replogle, L. A. Gilbert, J. E. Villalta, S. E. Torigoe, R. Tjian, J. S. Weissman, Nucleosomes impede Cas9 access to DNA in vivo and in vitro. *eLife* **5**, 2767 (2016).[doi:10.7554/eLife.12677](https://doi.org/10.7554/eLife.12677) [Medline](#)
  30. S. Djebali, C. A. Davis, A. Merkel, A. Dobin, T. Lassmann, A. Mortazavi, A. Tanzer, J. Lagarde, W. Lin, F. Schlesinger, C. Xue, G. K. Marinov, J. Khatun, B. A. Williams, C. Zaleski, J. Rozowsky, M. Röder, F. Kokocinski, R. F. Abdelhamid, T. Alioto, I. Antoshechkin, M. T. Baer, N. S. Bar, P. Batut, K. Bell, I. Bell, S. Chakraborty, X. Chen, J. Chrast, J. Curado, T. Derrien, J. Drenkow, E. Dumais, J. Dumais, R. Duttagupta, E. Falconnet, M. Fastuca, K. Fejes-Toth, P. Ferreira, S. Foissac, M. J. Fullwood, H. Gao, D. Gonzalez, A. Gordon, H. Gunawardena, C. Howald, S. Jha, R. Johnson, P. Kapranov, B. King, C. Kingswood, O. J. Luo, E. Park, K. Persaud, J. B. Preall, P. Ribeca, B. Risk, D. Robyr, M. Sammeth, L. Schaffer, L.-H. See, A. Shahab, J. Skancke, A. M. Suzuki, H. Takahashi, H. Tilgner, D. Trout, N. Walters, H. Wang, J. Wrobel, Y. Yu, X. Ruan, Y. Hayashizaki, J. Harrow, M. Gerstein, T. Hubbard, A. Reymond, S. E. Antonarakis, G. Hannon, M. C. Giddings, Y. Ruan, B. Wold, P. Carninci, R. Guigó, T. R. Gingeras, Landscape of transcription in human cells. *Nature* **489**, 101–108 (2012).[doi:10.1038/nature11233](https://doi.org/10.1038/nature11233) [Medline](#)
  31. B. Chen, L. A. Gilbert, B. A. Cimini, J. Schnitzbauer, W. Zhang, G.-W. Li, J. Park, E. H. Blackburn, J. S. Weissman, L. S. Qi, B. Huang, Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. *Cell* **155**, 1479–1491 (2013).[doi:10.1016/j.cell.2013.12.001](https://doi.org/10.1016/j.cell.2013.12.001) [Medline](#)
  32. B. Langmead, C. Trapnell, M. Pop, S. L. Salzberg, Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol.* **10**, R25 (2009).[doi:10.1186/gb-2009-10-3-r25](https://doi.org/10.1186/gb-2009-10-3-r25) [Medline](#)
  33. Q. Li, J. B. Brown, H. Huang, P. J. Bickel, Measuring reproducibility of high-throughput experiments. *arXiv stat.AP* (2011), pp. 1752–1779.
  34. W. J. Kent, C. W. Sugnet, T. S. Furey, K. M. Roskin, T. H. Pringle, A. M. Zahler, D. Haussler, The human genome browser at UCSC. *Genome Res.* **12**, 996–1006 (2002).[doi:10.1101/gr.229102](https://doi.org/10.1101/gr.229102) [Article published online before print in May 2002](#) [Medline](#)
  35. C. E. Grant, T. L. Bailey, W. S. Noble, FIMO: Scanning for occurrences of a given motif. *Bioinformatics* **27**, 1017–1018 (2011).[doi:10.1093/bioinformatics/btr064](https://doi.org/10.1093/bioinformatics/btr064) [Medline](#)
  36. V. Matys, O. V. Kel-Margoulis, E. Fricke, I. Liebich, S. Land, A. Barre-Dirrie, I. Reuter, D. Chekmenev, M. Krull, K. Hornischer, N. Voss, P. Stegmaier, B. Lewicki-Potapov, H. Saxel, A. E. Kel, E. Wingender, TRANSFAC and its module TRANSCmpel: Transcriptional gene regulation in eukaryotes. *Nucleic Acids Res.* **34**, D108–D110 (2006).[doi:10.1093/nar/gkj143](https://doi.org/10.1093/nar/gkj143) [Medline](#)
  37. H. Xu, T. Xiao, C.-H. Chen, W. Li, C. A. Meyer, Q. Wu, D. Wu, L. Cong, F. Zhang, J. S. Liu, M. Brown, X. S. Liu, Sequence determinants of improved CRISPR sgRNA design. *Genome Res.* **25**, 1147–1157 (2015).[doi:10.1101/gr.191452.115](https://doi.org/10.1101/gr.191452.115) [Medline](#)
  38. N. E. Sanjana, O. Shalem, F. Zhang, Improved vectors and genome-wide libraries for CRISPR screening. *Nat. Methods* **11**, 783–784 (2014).[doi:10.1038/nmeth.3047](https://doi.org/10.1038/nmeth.3047) [Medline](#)
  39. J. M. Engreitz, K. Sirokman, P. McDonel, A. A. Shishkin, C. Surka, P. Russell, S. R. Grossman, A. Y. Chow, M. Guttman, E. S. Lander, RNA-RNA interactions enable specific targeting of noncoding RNAs to nascent Pre-mRNAs and chromatin sites. *Cell* **159**, 188–199 (2014).[doi:10.1016/j.cell.2014.08.018](https://doi.org/10.1016/j.cell.2014.08.018) [Medline](#)
  40. M. I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).[doi:10.1186/s13059-014-0550-8](https://doi.org/10.1186/s13059-014-0550-8) [Medline](#)
  41. M. Garber, N. Yosef, A. Goren, R. Raychowdhury, A. Thielke, M. Guttman, J. Robinson, B. Minie, N. Chevrier, Z. Itzhaki, R. Blecher-Gonen, C. Bornstein, D. Amann-Zalcenstein, A. Weiner, D. Friedrich, J. Meldrim, O. Ram, C. Cheng, A. Gnirke, S. Fisher, N. Friedman, B. Wong, B. E. Bernstein, C. Nusbaum, N. Hacohen, A. Regev, I. Amit, A high-throughput chromatin immunoprecipitation approach reveals principles of dynamic gene regulation in mammals. *Mol. Cell* **47**, 810–822 (2012).[doi:10.1016/j.molcel.2012.07.030](https://doi.org/10.1016/j.molcel.2012.07.030) [Medline](#)
  42. L. Cong, F. A. Ran, D. Cox, S. Lin, R. Barretto, N. Habib, P. D. Hsu, X. Wu, W. Jiang, L. A. Marraffini, F. Zhang, Multiplex genome engineering using CRISPR/Cas systems. *Science* **339**, 819–823 (2013).[doi:10.1126/science.1231143](https://doi.org/10.1126/science.1231143) [Medline](#)
  43. J. Ernst, P. Kheradpour, T. S. Mikkelsen, N. Shores, L. D. Ward, C. B. Epstein, X. Zhang, L. Wang, R. Issner, M. Coyne, M. Ku, T. Durham, M. Kellis, B. E. Bernstein, Mapping and analysis of chromatin state dynamics in nine human cell types. *Nature* **473**, 43–49 (2011).[doi:10.1038/nature09906](https://doi.org/10.1038/nature09906) [Medline](#)
  44. R. E. Thurman, E. Rynes, R. Humbert, J. Vierstra, M. T. Maurano, E. Haugen, N. C. Sheffield, A. B. Stergachis, H. Wang, B. Vernot, K. Garg, S. John, R. Sandstrom, D. Bates, L. Boatman, T. K. Canfield, M. Diegel, D. Dunn, A. K. Ebersol, T. Frum, E. Giste, A. K. Johnson, E. M. Johnson, T. Kutayavin, B. Lajoie, B.-K. Lee, K. Lee, D. London, D. Lotakis, S. Neph, F. Neri, E. D. Nguyen, H. Qu, A. P. Reynolds, V. Roach, A. Safi, M. E. Sanchez, A. Sanyal, A. Shafer, J. M. Simon, L. Song, S. Vong, M. Weaver, Y. Yan, Z. Zhang, Z. Zhang, B. Lenhard, M. Tewari, M. O. Dorschner, R. S. Hansen, P. A. Navas, G. Stamatoiyannopoulos, V. R. Iyer, J. D. Lieb, S. R. Sunyaev, J. M. Akey, P. J. Sabo, R. Kaul, T. S. Furey, J. Dekker, G. E. Crawford, J. A. Stamatoiyannopoulos, The accessible chromatin landscape of the human genome. *Nature* **489**, 75–82 (2012).[doi:10.1038/nature11232](https://doi.org/10.1038/nature11232) [Medline](#)
  45. O. Corradin, A. Saiakhova, B. Akhtar-Zaidi, L. Myeroff, J. Willis, R. Cowper-Sal-lari, M. Lupien, S. Markowitz, P. C. Scacheri, Combinatorial effects of multiple enhancer variants in linkage disequilibrium dictate levels of gene expression to confer susceptibility to common traits. *Genome Res.* **24**, 1–13 (2014).[doi:10.1101/gr.164079.113](https://doi.org/10.1101/gr.164079.113) [Medline](#)
  46. B. Tolhuis, R. J. Palstra, E. Splinter, F. Grosveld, W. de Laat, Looping and interaction between hypersensitive sites in the active beta-globin locus. *Mol. Cell* **10**, 1453–1465 (2002).[doi:10.1016/S1097-2765\(02\)00781-5](https://doi.org/10.1016/S1097-2765(02)00781-5) [Medline](#)
  47. J. Dekker, T. Misteli, Long-range chromatin interactions. *Cold Spring Harb. Perspect. Biol.* **7**, a019356 (2015).[doi:10.1101/cshperspect.a019356](https://doi.org/10.1101/cshperspect.a019356) [Medline](#)
  48. W. Deng, J. Lee, H. Wang, J. Miller, A. Reik, P. D. Gregory, A. Dean, G. A. Blobel, Controlling long-range genomic interactions at a native locus by targeted tethering of a looping factor. *Cell* **149**, 1233–1244 (2012).[doi:10.1016/j.cell.2012.03.051](https://doi.org/10.1016/j.cell.2012.03.051) [Medline](#)
  49. W. Deng, J. W. Rupon, I. Krivega, L. Breda, I. Motta, K. S. Jahn, A. Reik, P. D. Gregory, S. Rivella, A. Dean, G. A. Blobel, Reactivation of developmentally silenced globin genes by forced chromatin looping. *Cell* **158**, 849–860 (2014).[doi:10.1016/j.cell.2014.05.050](https://doi.org/10.1016/j.cell.2014.05.050) [Medline](#)
  50. B. He, C. Chen, L. Teng, K. Tan, Global view of enhancer-promoter interactome in human cells. *Proc. Natl. Acad. Sci. U.S.A.* **111**, E2191–E2199 (2014).[doi:10.1073/pnas.1320308111](https://doi.org/10.1073/pnas.1320308111) [Medline](#)
  51. S. Whalen, R. M. Truty, K. S. Pollard, Enhancer-promoter interactions are encoded by complex genomic signatures on looping chromatin. *Nat. Genet.* **48**, 488–496 (2016).[doi:10.1038/ng.3539](https://doi.org/10.1038/ng.3539) [Medline](#)
  52. R. J. H. Ryan, Y. Drier, H. Whitton, M. J. Cotton, J. Kaur, R. Issner, S. Gillespie, C. B. Epstein, V. Nardi, A. R. Sohani, E. P. Hochberg, B. E. Bernstein, Detection of enhancer-associated rearrangements reveals mechanisms of oncogene dysregulation in B-cell lymphoma. *Cancer Discov.* **5**, 1058–1071 (2015).[doi:10.1158/2159-8290.CD-15-0370](https://doi.org/10.1158/2159-8290.CD-15-0370) [Medline](#)
  53. J. Huang, X. Liu, D. Li, Z. Shao, H. Cao, Y. Zhang, E. Trompouki, T. V. Bowman, L. I. Zon, G.-C. Yuan, S. H. Orkin, J. Xu, Dynamic control of enhancer repertoires drives lineage and stage-specific transcription during hematopoiesis. *Dev. Cell* **36**, 9–23 (2016).[doi:10.1016/j.devcel.2015.12.014](https://doi.org/10.1016/j.devcel.2015.12.014) [Medline](#)
  54. J. R. Dixon, I. Jung, S. Selvaraj, Y. Shen, J. E. Antosiewicz-Bourget, A. Y. Lee, Z. Ye, A. Kim, N. Rajagopal, W. Xie, Y. Diao, J. Liang, H. Zhao, V. V. Lobanenkov, J. R. Ecker, J. A. Thomson, B. Ren, Chromatin architecture reorganization during stem cell differentiation. *Nature* **518**, 331–336 (2015).[doi:10.1038/nature14222](https://doi.org/10.1038/nature14222) [Medline](#)
  55. S. Tuupanen, M. Turunen, R. Lehtonen, O. Hallikas, S. Vanharanta, T. Kivioja, M. Björklund, G. Wei, J. Yan, I. Niittymäki, J.-P. Mecklin, H. Järvinen, A. Ristimäki, M. Di-Bernardo, P. East, L. Carvajal-Carmona, R. S. Houlston, I. Tomlinson, K. Palin, E. Ukkonen, A. Karhu, J. Taipale, L. A. Aaltonen, The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. *Nat. Genet.* **41**, 885–890 (2009).[doi:10.1038/ng.406](https://doi.org/10.1038/ng.406) [Medline](#)
  56. J. B. Wright, S. J. Brown, M. D. Cole, Upregulation of c-MYC in cis through a large chromatin loop linked to a cancer risk-associated single-nucleotide polymorphism in colorectal cancer cells. *Mol. Cell Biol.* **30**, 1411–1420



- (2010).[doi:10.1128/MCB.01384-09](https://doi.org/10.1128/MCB.01384-09) [Medline](#)
57. I. K. Sur, O. Hallikas, A. Vähärautio, J. Yan, M. Turunen, M. Enge, M. Taipale, A. Karhu, L. A. Aaltonen, J. Taipale, Mice lacking a Myc enhancer that includes human SNP rs6983267 are resistant to intestinal tumors. *Science* **338**, 1360–1363 (2012).[doi:10.1126/science.1228606](https://doi.org/10.1126/science.1228606) [Medline](#)
  58. D. Herranz, A. Ambesi-Impiombato, T. Palomero, S. A. Schnell, L. Belver, A. A. Wendorff, L. Xu, M. Castillo-Martin, D. Llobet-Navás, C. Cordon-Cardo, E. Clappier, J. Soulier, A. A. Ferrando, A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. *Nat. Med.* **20**, 1130–1137 (2014).[doi:10.1038/nm.3665](https://doi.org/10.1038/nm.3665) [Medline](#)
  59. Y. Yashiro-Ohtani, H. Wang, C. Zang, K. L. Arnett, W. Bailis, Y. Ho, B. Knoechel, C. Lanauze, L. Louis, K. S. Forsyth, S. Chen, Y. Chung, J. Schug, G. A. Blobel, S. A. Liebhaber, B. E. Bernstein, S. C. Blacklow, X. S. Liu, J. C. Aster, W. S. Pear, Long-range enhancer activity determines Myc sensitivity to Notch inhibitors in T cell leukemia. *Proc. Natl. Acad. Sci. U.S.A.* **111**, E4946–E4953 (2014).[doi:10.1073/pnas.1407079111](https://doi.org/10.1073/pnas.1407079111) [Medline](#)
  60. J. Shi, W. A. Whyte, C. J. Zepeda-Mendoza, J. P. Milazzo, C. Shen, J.-S. Roe, J. L. Minder, F. Mercan, E. Wang, M. A. Eckersley-Maslin, A. E. Campbell, S. Kawaoka, S. Shareef, Z. Zhu, J. Kendall, M. Muhar, C. Haslinger, M. Yu, R. G. Roeder, M. H. Wigler, G. A. Blobel, J. Zuber, D. L. Spector, R. A. Young, C. R. Vakoc, Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation. *Genes Dev.* **27**, 2648–2662 (2013).[doi:10.1101/gad.232710.113](https://doi.org/10.1101/gad.232710.113) [Medline](#)
  61. L. D. Ward, M. Kellis, HaploReg: A resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. *Nucleic Acids Res.* **40**, D930–D934 (2012).[doi:10.1093/nar/gkr917](https://doi.org/10.1093/nar/gkr917) [Medline](#)
  62. R. C. Gentleman, V. J. Carey, D. M. Bates, B. Bolstad, M. Dettling, S. Dudoit, B. Ellis, L. Gautier, Y. Ge, J. Gentry, K. Hornik, T. Hothorn, W. Huber, S. Iacus, R. Irizarry, F. Leisch, C. Li, M. Maechler, A. J. Rossini, G. Sawitzki, C. Smith, G. Smyth, L. Tierney, J. Y. H. Yang, J. Zhang, Bioconductor: Open software development for computational biology and bioinformatics. *Genome Biol.* **5**, R80 (2004).[doi:10.1186/gb-2004-5-10-r80](https://doi.org/10.1186/gb-2004-5-10-r80) [Medline](#)
  63. M. Lawrence, W. Huber, H. Pagès, P. Aboyoun, M. Carlson, R. Gentleman, M. T. Morgan, V. J. Carey, Software for computing and annotating genomic ranges. *PLOS Comput. Biol.* **9**, e1003118 (2013).[doi:10.1371/journal.pcbi.1003118](https://doi.org/10.1371/journal.pcbi.1003118) [Medline](#)
  64. M. Lawrence, R. Gentleman, V. Carey, rtracklayer: An R package for interfacing with genome browsers. *Bioinformatics* **25**, 1841–1842 (2009).[doi:10.1093/bioinformatics/btp328](https://doi.org/10.1093/bioinformatics/btp328) [Medline](#)
  65. A. R. Quinlan, I. M. Hall, BEDTools: A flexible suite of utilities for comparing genomic features. *Bioinformatics* **26**, 841–842 (2010).[doi:10.1093/bioinformatics/btq033](https://doi.org/10.1093/bioinformatics/btq033) [Medline](#)
  66. J. T. Robinson, H. Thorvaldsdóttir, W. Winckler, M. Guttman, E. S. Lander, G. Getz, J. P. Mesirov, Integrative genomics viewer. *Nat. Biotechnol.* **29**, 24–26 (2011).[doi:10.1038/nbt.1754](https://doi.org/10.1038/nbt.1754) [Medline](#)
  67. P. J. A. Cock, T. Antao, J. T. Chang, B. A. Chapman, C. J. Cox, A. Dalke, I. Friedberg, T. Hamelryck, F. Kauff, B. Wilczynski, M. J. L. de Hoon, Biopython: Freely available Python tools for computational molecular biology and bioinformatics. *Bioinformatics* **25**, 1422–1423 (2009).[doi:10.1093/bioinformatics/btp163](https://doi.org/10.1093/bioinformatics/btp163) [Medline](#)
  68. T. Wang, J. J. Wei, D. M. Sabatini, E. S. Lander, Genetic screens in human cells using the CRISPR-Cas9 system. *Science* **343**, 80–84 (2014).[doi:10.1126/science.1246981](https://doi.org/10.1126/science.1246981) [Medline](#)
  69. O. Shalem, N. E. Sanjana, E. Hartenian, X. Shi, D. A. Scott, T. S. Mikkelsen, D. Heckl, B. L. Ebert, D. E. Root, J. G. Doench, F. Zhang, Genome-scale CRISPR-Cas9 knockout screening in human cells. *Science* **343**, 84–87 (2014).[doi:10.1126/science.1247005](https://doi.org/10.1126/science.1247005) [Medline](#)
  70. O. Parnas, M. Jovanovic, T. M. Eisenhaure, R. H. Herbst, A. Dixit, C. J. Ye, D. Przybylski, R. J. Platt, I. Tirosh, N. E. Sanjana, O. Shalem, R. Satija, R. Raychowdhury, P. Mertins, S. A. Carr, F. Zhang, N. Hacohen, A. Regev, A genome-wide CRISPR screen in primary immune cells to dissect regulatory networks. *Cell* **162**, 675–686 (2015).[doi:10.1016/j.cell.2015.06.059](https://doi.org/10.1016/j.cell.2015.06.059) [Medline](#)
  71. Y. Guan, W.-L. Kuo, J. L. Stilwell, H. Takano, A. V. Lapuk, J. Fridlyand, J.-H. Mao, M. Yu, M. A. Miller, J. L. Santos, S. E. Kalogier, J. W. Carlson, D. G. Ginzinger, S. E. Celniker, G. B. Mills, D. G. Huntsman, J. W. Gray, Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. *Clin. Cancer Res.* **13**, 5745–5755 (2007).[doi:10.1158/1078-0432.CCR-06-2882](https://doi.org/10.1158/1078-0432.CCR-06-2882) [Medline](#)
  72. Y.-Y. Tseng, B. S. Moriarity, W. Gong, R. Akiyama, A. Tiwari, H. Kawakami, P. Ronning, B. Reuland, K. Guenther, T. C. Beadnell, J. Essig, G. M. Otto, M. G. O'Sullivan, D. A. Largaespada, K. L. Schwertfeger, Y. Marahrens, Y. Kawakami, A. Bagchi, PVT1 dependence in cancer with MYC copy-number increase. *Nature* **512**, 82–86 (2014). [Medline](#)
  73. J. M. Engreitz *et al.*, Neighborhood regulation by lncRNA promoters, transcription, and splicing. *bioRxiv* 050948 (2016).
  74. V. R. Paralkar, C. C. Tabora, P. Huang, Y. Yao, A. V. Kossenkov, R. Prasad, J. Luan, J. O. J. Davies, J. R. Hughes, R. C. Hardison, G. A. Blobel, M. J. Weiss, Unlinking an lncRNA from its associated cis element. *Mol. Cell* **62**, 104–110 (2016).[doi:10.1016/j.molcel.2016.02.029](https://doi.org/10.1016/j.molcel.2016.02.029) [Medline](#)
  75. S. L. Ameres, P. D. Zamore, Diversifying microRNA sequence and function. *Nat. Rev. Mol. Cell Biol.* **14**, 475–488 (2013).[doi:10.1038/nrm3611](https://doi.org/10.1038/nrm3611) [Medline](#)
  76. M. J. Guertin, A. L. Martins, A. Siepel, J. T. Lis, Accurate prediction of inducible transcription factor binding intensities in vivo. *PLOS Genet.* **8**, e1002610 (2012).[doi:10.1371/journal.pgen.1002610](https://doi.org/10.1371/journal.pgen.1002610) [Medline](#)
  77. C. D. Arnold, D. Gerlach, C. Stelzer, L. M. Boryń, M. Rath, A. Stark, Genome-wide quantitative enhancer activity maps identified by STARR-seq. *Science* **339**, 1074–1077 (2013).[doi:10.1126/science.1232542](https://doi.org/10.1126/science.1232542) [Medline](#)
  78. M. P. Creighton, A. W. Cheng, G. G. Welstead, T. Kooistra, B. W. Carey, E. J. Steine, J. Hanna, M. A. Lodato, G. M. Frampton, P. A. Sharp, L. A. Boyer, R. A. Young, R. Jaenisch, Histone H3K27ac separates active from poised enhancers and predicts developmental state. *Proc. Natl. Acad. Sci. U.S.A.* **107**, 21931–21936 (2010).[doi:10.1073/pnas.1016071107](https://doi.org/10.1073/pnas.1016071107) [Medline](#)
  79. S. Bonn, R. P. Zinzen, C. Girardot, E. H. Gustafson, A. Perez-Gonzalez, N. Delhomme, Y. Ghavi-Helm, B. Wilczyński, A. Riddell, E. E. M. Furlong, Tissue-specific analysis of chromatin state identifies temporal signatures of enhancer activity during embryonic development. *Nat. Genet.* **44**, 148–156 (2012).[doi:10.1038/ng.1064](https://doi.org/10.1038/ng.1064) [Medline](#)
  80. E. Lieberman-Aiden, N. L. van Berkum, L. Williams, M. Imakaev, T. Ragozcy, A. Telling, I. Amit, B. R. Lajoie, P. J. Sabo, M. O. Dorschner, R. Sandstrom, B. Bernstein, M. A. Bender, M. Groudine, A. Gnirke, J. Stamatoyannopoulos, L. A. Mirny, E. S. Lander, J. Dekker, Comprehensive mapping of long-range interactions reveals folding principles of the human genome. *Science* **326**, 289–293 (2009).[doi:10.1126/science.1181369](https://doi.org/10.1126/science.1181369) [Medline](#)
  81. M. Rylski, J. J. Welch, Y.-Y. Chen, D. L. Letting, J. A. Diehl, L. A. Chodosh, G. A. Blobel, M. J. Weiss, GATA-1-mediated proliferation arrest during erythroid maturation. *Mol. Cell Biol.* **23**, 5031–5042 (2003).[doi:10.1128/MCB.23.14.5031-5042.2003](https://doi.org/10.1128/MCB.23.14.5031-5042.2003) [Medline](#)
  82. Y. Woon Kim, S. Kim, C. Geun Kim, A. Kim, The distinctive roles of erythroid specific activator GATA-1 and NF-E2 in transcription of the human fetal  $\gamma$ -globin genes. *Nucleic Acids Res.* **39**, 6944–6955 (2011).[doi:10.1093/nar/gkr253](https://doi.org/10.1093/nar/gkr253) [Medline](#)
  83. Q. Gong, A. Dean, Enhancer-dependent transcription of the epsilon-globin promoter requires promoter-bound GATA-1 and enhancer-bound AP-1/NF-E2. *Mol. Cell Biol.* **13**, 911–917 (1993).[doi:10.1128/MCB.13.2.911](https://doi.org/10.1128/MCB.13.2.911) [Medline](#)

#### ACKNOWLEDGMENTS

We thank T. Wang and R. Issner for technical advice and reagents; and R. Ryan, B. Bernstein, N. Sanjana, J. Wright, and F. Zhang for discussions. This work was supported by funds from the Broad Institute (E.S.L.). C.P.F. is supported by the National Defense Science and Engineering Graduate Fellowship. J.M.E. is supported by the Fannie and John Hertz Foundation. M.M. is supported by a DFG Research Fellowship. S.R.G. is supported by NIGMS T32GM007753. The Broad Institute, which E.S.L. directs, holds patents and has filed patent applications on technologies related to other aspects of CRISPR. J.M.E., C.P.F., and E.S.L. are inventors on a patent application filed by the Broad Institute related to this work (U.S. no. 62/401,149). Data presented in this paper can be found in the supplemental materials. Author Contributions: J.M.E. conceived the study. J.M.E., C.P.F., M.M., and S.R.G. designed experiments. C.P.F., M.M., R.A., G.M., E.M.P., M.K., and J.M.E. performed experiments. C.P.F., J.M.E., and B.C. analyzed data. C.P.F., J.M.E., and E.S.L. wrote the manuscript with input from all authors.

**SUPPLEMENTARY MATERIALS**

[www.sciencemag.org/cgi/content/full/science.aag2445/DC1](http://www.sciencemag.org/cgi/content/full/science.aag2445/DC1)

Materials and Methods

Supplementary Text

Figs. S1 to S9

Tables S1 to S3


References (26–83)

29 May 2016; accepted 21 September 2016


Published online 29 September 2016

10.1126/science.aag2445






**Fig. 1. Systematic mapping of noncoding elements that regulate *GATA1*.** (A) CRISPRi method for identifying gene regulatory elements. Cells expressing KRAB-dCas9 from a dox-inducible promoter are infected with a pool of single guide RNAs (sgRNAs) targeting every possible site across a region of interest. In a proliferation-based screen, cells expressing sgRNAs that target essential regulatory elements will be depleted in the final population. (B) CRISPRi screen results in the *GATA1* locus. A high CRISPRi score indicates strong depletion over the course of the screen. Red boxes: Windows showing significant depletion compared to negative control sgRNAs (13). DNase I hypersensitivity, H3K27ac ChIP-Seq, and histone modification annotations (ChromHMM) in K562 cells are from ENCODE (4). (C) Close-up of e-GATA1 and e-HDAC6. sgRNA track shows CRISPRi scores for each individual sgRNA in the region. White bar in GATA1 ChIP-seq track represents the GATA1 motif. (D) qPCR for GATA1 and HDAC6 mRNA in cells expressing individual sgRNAs. KRAB-dCas9 expression was activated for 24 hours before measurement. Gray bars: different sgRNAs for each target. Ctrl: negative control sgRNAs without a genomic target. Error bars: 95% confidence intervals (CI) for the mean of 3 biological replicates (13). \*:  $p < 0.05$  in *t* test versus Ctrl.



**Fig. 2. Identification and prediction of elements that regulate MYC.** (A) CRISPRi screening identifies 7 distal enhancers (e1-e7) that activate *MYC* and two repressive elements (r1, r2) that may act to repress *MYC*. NS1: an element that does not score in the screen. (B) 18-kb windows around each of the 7 distal enhancers. Y-axis scales are equivalent between panels. (C) qPCR for *MYC* mRNA in cells expressing individual sgRNAs 24 hours after KRAB-dCas9 activation. Gray bars: 2 different sgRNAs per target, or 5 for non-targeting controls (Ctrl). Error bars: 95% CI for the mean of 12 biological replicates (13). \*:  $p < 0.05$  in  $t$  test versus negative controls. (D) Correlation between *MYC* expression and relative cell viability for e1-e7, *MYC* TSS, NS1, and Ctrl sgRNAs (13). Pearson's  $R = 0.92$  includes e1-e7 sgRNAs only; with the others,  $R = 0.95$ . (E) Predicted impact of DHS elements on *MYC* expression (a function of quantitative DHS, H3K27ac, and Hi-C signal) versus their experimentally derived CRISPRi scores (13).





**Fig. 3. A heuristic model predicts disease-associated *MYC* enhancers across cell types.** (A) H3K27ac occupancy around *MYC* varies among 8 cell types and primary tissues. Black arrows: elements highlighted in panels below. (B) Locations of 4 enhancers previously shown to regulate *MYC* expression in other cell types and their predicted impact in a corresponding cell type. Points show predicted impact of 2-kb windows tiled in 100-bp increments across the *MYC* locus (13). T-ALL: T-cell acute lymphoblastic leukemia. AML: Acute myeloid leukemia. For each cell type, predicted impact is calculated based on available data (13). (C) Haplotype blocks of SNPs linked to human diseases and phenotypes ( $R^2 > 0.8$  with index SNP in genome-wide association study). (D) SNPs associated with bladder cancer and Hodgkin's lymphoma overlap regulatory elements predicted by our metric to regulate *MYC* in a corresponding cell type or tissue. A SNP associated with height overlaps a conserved element that is active only in chondrocytes. Karpas422: diffuse large B cell lymphoma cell line.

EXTENDED PDF FORMAT  
SPONSORED BY



**Systematic mapping of functional enhancer-promoter connections  
with CRISPR interference**

Charles P. Fulco, Mathias Munschauer, Rockwell Anyoha, Glen Munson, Sharon R. Grossman, Elizabeth M. Perez, Michael Kane, Brian Cleary, Eric S. Lander and Jesse M. Engreitz (September 29, 2016)  
published online September 29, 2016 originally published online September 29, 2016

Editor's Summary

---

This copy is for your personal, non-commercial use only.

---

- Article Tools** Visit the online version of this article to access the personalization and article tools:  
<http://science.sciencemag.org/content/early/2016/10/05/science.aag2445>
- Permissions** Obtain information about reproducing this article:  
<http://www.sciencemag.org/about/permissions.dtl>

*Science* (print ISSN 0036-8075; online ISSN 1095-9203) is published weekly, except the last week in December, by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. Copyright 2016 by the American Association for the Advancement of Science; all rights reserved. The title *Science* is a registered trademark of AAAS.